Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
BMC Cancer|August 23, 2022
Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 studyLuigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
Scientific Reports|January 23, 2023
Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)Luigi Celio, Diego Cortinovis, Alessio Aligi Cogoni, et al.
Diagnostics (Basel, Switzerland)|May 24, 2024
Rare Driver Mutations in Advanced, Oncogene-Addicted Non-Small Cell Lung Cancer: A North Italian, Real-World, Registry ExperienceKalliopi Andrikou, Paola Ulivi, Elisabetta Petracci, et al.
Clinical Lung Cancer|April 12, 2020
Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective StudyRoberta Minari, Giulia Mazzaschi, Paola Bordi, et al.
Cells|January 11, 2022
Immunotherapy in Nonendemic Nasopharyngeal Carcinoma: Real-World Data from Two Nonendemic RegionsPanagiota Economopoulou, Anastasios Pantazopoulos, Aris Spathis, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2026
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP studyMaria Gemelli, Luca Sala, Alessandro Morabito, et al.
Lung Cancer (Amsterdam, Netherlands)|November 15, 2022
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)Antonio Passaro, Giuseppe Lo Russo, Francesco Passiglia, et al.
Cancers|April 23, 2022
Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring <i>BRAF</i> Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E SubgroupsFabiana Perrone, Giulia Mazzaschi, Roberta Minari, et al.
Clinical Lung Cancer|March 26, 2021
The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLCMarco Perna, Vieri Scotti, Patrizia Ciammella, et al.
Frontiers in Oncology|October 15, 2021
A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung CancerAlessio Bruni, Vieri Scotti, Paolo Borghetti, et al.
Pageof 10